TABLE 3.
Univariate analysis of survival rates for naive‐RT patients by Cox regression
| Variables | OS | PFS | LPFS | DMFS | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender (male as ref.) | 0.4 (0.11‐1.55) | .19 | 0.47 (0.2‐1.1) | .08 | 0.27 (0.06‐1.3) | 1.0 | 0.52 (0.16‐1.73) | .29 |
| Age (≤49 y vs >49 y) | 0.96 (0.28‐3.31 | .95 | 1.14 (0.5‐2.56) | .76 | 1.36 (0.36‐5.05) | .65 | 1.16 (0.37‐3.69) | .80 |
| Histology (others as ref.) | ||||||||
| Sarcoma | 12.73 (2.5‐66.27) | .003 | 2.7 (1.04‐6.96) | .041 | 0.98 (2.0‐4.73) | .98 | 3.18 (0.85‐11.9) | .09 |
| Melanoma | 8.93 (1.48‐53.71) | .017 | 3.9 (1.42‐10.78) | .008 | 0 | .99 | 4.38 (1.04‐18.9) | .048 |
| T categories (T1/2 vs T3/4) | 0.3 (0.88‐1.03) | .056 | 0.38 (0.15‐0.96) | .041 | 0.6 (0.12‐2.9) | .53 | 0.42 (0.11‐1.55) | .19 |
| N categories (N0 vs N1‐3) | 2.63 (0.68‐10.2) | .16 | 2.75 (1.08‐7.02) | .035 | 0.76 (0.1‐6.08) | .80 | 2.65 (0.71‐9.88) | .15 |
| GTV (continuous variable) | 1.01 (1.0‐1.02) | .06 | 1.01 (1.0‐1.01) | .09 | 1.0 (1.0‐1.02) | .54 | 1.01 (1.0‐1.02) | .1 |
| Surgery (surgery vs without surgery + biopsy) | 1.55 (0.41‐5.89) | .52 | 1.1 (0.47‐2.58) | .82 | 1.015 (0.29‐4.6) | .84 | 0.78 (0.25‐2.45) | .67 |
| BED (continuous variable) | 1.19 (1.01‐1.39) | .033 | 1.14 (1.02‐1.27) | .019 | 1.13 (0.94‐1.35) | .21 | 1.09 (0.94‐1.27) | .26 |
Abbreviations: BED, biological equivalent dose; DMFS, distant metastasis‐free survival; HR, Hazard ratio; LPFS, local progression‐free survival; OS, overall survival; PFS, progression‐free survival.
Statistically significant differences indicated in bold type.